Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.55 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7269957 | 0.98 | S1PR1 (0.57) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7269965 | 0.98 | S1PR1 (0.57) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7277972 | 0.94 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL856300 | 0.94 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL7278231 | 0.94 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL28211526 | 0.89 | S1PR1 (0.49) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL4375455 | 0.86 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| SCHEMBL9155196 | 0.86 | S1PR1 (0.41) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| Fluoride SCHEMBL30330897 | 0.83 | S1PR1 (0.56) | S1PR1S1PR3S1PR5S1PR4SPHK2 | |
| Hydrochloric Acid SCHEMBL30330555 | 0.83 | S1PR1 (0.56) | S1PR1S1PR3S1PR5S1PR4SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1649857-A2 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2006-04-26 | — | — | EP | claimed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-20130281523-A1 | LOW DOSE CANNABINOID MEDICAMENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2013-10-24 | — | — | US | disclosed |
| EP-2640379-A2 | LOW DOSE CANNABINOID MEDICAMENTS | Pier Pharmaceuticals (US) | 2013-09-25 | — | — | EP | disclosed |
| US-20120231083-A1 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2012068516-A2 | LOW DOSE CANNABINOID MEDICAMENTS | PIER PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| US-8178496-B2 | Photoreactive regulator of glutamate receptor function and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011063164-A2 | SUSTAINED RELEASE CANNABINOID MEDICAMENTS | STEADY SLEEP RX CO., INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20090181454-A1 | PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF | ENERGY, UNITED STATE DEPARTMENT OF | 2009-07-16 | — | — | US | disclosed |
| US-20050054650-A1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | disclosed |
| EP-1427404-A2 | TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS | Nedergaard, Maiken (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20030050224-A1 | Blocking glutamate function at an ionotropic glutamate receptor. e.g., N-methyl-D-aspartate receptor, the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid receptor and the kainate receptor; brain disorders; spinal chord | NEDERGAARD MAIKEN (US) | 2003-03-13 | — | — | US | disclosed |
| WO-2003015713-A2 | TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS | NEDERGAARD MAIKEN (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | disclosed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181454-A1 | PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF | GRM2, GRM1, GRM3 | S1PR1 2408/4885S1PR3 2183/4885S1PR5 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.